Document is current
Any future updates will be listed below
-
Authors
Baker, Stephen https://orcid.org/0000-0002-7797-9080
Krishna, Aishwarya
Higham, Sophie https://orcid.org/0000-0003-4139-7780
Naydenova, Plamena
O’Leary, Siobhan
Scott, Josefin Bartholdson https://orcid.org/0000-0003-3380-4446
Harcourt, Katherine
Forrest, Sally
Goulding, David
Thi Nguyen, To Nguyen
Toan, Nguyen Duc
Alekseeva, Elizaveta
Zhou, Qingqing
Andreozzi, Ilaria
Sobotic, Barbara
Craig, Hannah
Wong, Vivian
Forrest-Owen, Nichola
Sanchez, Dana Moreno
Pearce, Claire
Roberts, Leah https://orcid.org/0000-0002-1024-0564
Watson, Simon https://orcid.org/0000-0002-1741-5742
Clare, Simon
Torok, Mili Estee https://orcid.org/0000-0001-9098-8590
Dougan, Gordon
Kellam, Paul https://orcid.org/0000-0003-3166-4734
Tregoning, John S. https://orcid.org/0000-0001-8093-8741
Reece, Stephen T. https://orcid.org/0000-0003-0725-6271
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation
- License Information
-
More Information
Article History
Received: 1 October 2023
Accepted: 4 September 2024
First Online: 12 September 2024
Competing interests
: The authors declare the following competing interests. J.B.S., Q.Z., and S.T.R. are employees of Kymab Ltd, a Sanofi company and may have held or continue to hold stock options or shares in Sanofi. S.O’.L., J.B.S., A.K., S.W., S.T.R., and S.B. are listed as inventors on a published patent WO2023094628A1 covering monoclonal antibodies generated by this work. S.O’.L., A.K., I.A., B.S., H.C., V.W., N.F.O., D.M.S., C.P., S.W., and P.K. were employees of Kymab, a Sanofi Company within the last three years and may have held or continue to hold stock options or shares in Sanofi. The other authors declare no competing interests.
